The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Article uri icon

Overview

publication date

  • August 8, 2016

Research

keywords

  • Cell Death
  • Enzyme Inhibitors
  • Heterocyclic Compounds, 4 or More Rings
  • Hodgkin Disease
  • Immunoconjugates
  • Mitosis
  • Phosphoinositide-3 Kinase Inhibitors

Identity

Scopus Document Identifier

  • 84984846907

Digital Object Identifier (DOI)

  • 10.1038/leu.2016.224

PubMed ID

  • 27499137

Additional Document Info

volume

  • 30

issue

  • 12